Glucagon (19-29), Human Mechanism, Clinical Value, and Resea

Glucagon (19-29), Human: Mechanism, Clinical Value, and Research Applications

Introduction
Glucagon (19-29), human, is a synthetic peptide corresponding to the C-terminal nonapeptide fragment of the full-length human glucagon molecule. Glucagon itself is a 29-amino acid peptide hormone produced by the alpha cells of the pancreas, playing a critical role in glucose homeostasis by stimulating hepatic glucose production via glycogenolysis and gluconeogenesis (Unger & Cherrington, 2012, Endocrine Reviews). The fragment Glucagon (19-29) represents the amino acid sequence from position 19 to 29 of the parent hormone, which has been shown to retain certain biological activities distinct from the full-length peptide. This fragment is also known as miniglucagon and has garnered interest for its potential as a modulator of glucagon receptor activity and as a research tool for dissecting glucagon’s physiological and pharmacological roles (Dalle et al., 2011, Diabetes). Mechanistically, Glucagon (19-29) is believed to act as a partial agonist or antagonist at the glucagon receptor, depending on the biological context and concentration. It may also interact with other G protein-coupled receptors (GPCRs) or modulate intracellular signaling pathways independently of the canonical glucagon receptor (Dalle et al., 2011). This unique pharmacological profile makes Glucagon (19-29) a valuable tool for investigating glucagon receptor signaling, glucose metabolism, and the development of novel therapeutics for metabolic diseases.

[Related: anhydrotetracycline] Clinical Value and Applications
The clinical value of Glucagon (19-29), human, is primarily rooted in its utility as a research tool rather than as a direct therapeutic agent. Its applications span several domains: 1. **Metabolic Disease Research:** Glucagon (19-29) is used to probe the physiological and pathological roles of glucagon signaling in glucose homeostasis, particularly in diabetes mellitus and hypoglycemic disorders (Dalle et al., 2011). [Related: nocodazole] 2. **Drug Discovery and Receptor Pharmacology:** The peptide serves as a model ligand for studying glucagon receptor structure-function relationships, aiding in the identification of novel agonists, antagonists, or allosteric modulators for therapeutic development (Holst et al., 2017, Nature Reviews Drug Discovery). 3. **Islet Biology:** Glucagon (19-29) is employed to investigate the paracrine interactions between pancreatic alpha and beta cells, elucidating the regulation of insulin and glucagon secretion (Gromada et al., 2007, Diabetes). [Related: a 83 01] 4. **Peptide Engineering:** As a minimal bioactive fragment, Glucagon (19-29) provides a template for designing stable, receptor-selective peptides with improved pharmacokinetic properties for potential therapeutic use (Knudsen et al., 2019, J Med Chem). While not currently approved for clinical therapy, the insights gained from research using Glucagon (19-29) inform the development of next-generation treatments for metabolic disorders.

Key Challenges and Pain Points Addressed
Current treatments for metabolic diseases such as type 2 diabetes and obesity often target insulin signaling or glucose uptake, with limited focus on the counter-regulatory hormone glucagon. However, dysregulation of glucagon secretion and action is increasingly recognized as a key contributor to hyperglycemia and impaired glucose tolerance (Unger & Cherrington, 2012). Traditional approaches using full-length glucagon or non-selective antagonists can lead to off-target effects, hypoglycemia, or loss of fine-tuned metabolic control. Glucagon (19-29) addresses several pain points in this context: - **Selective Modulation:** As a fragment with partial agonist/antagonist properties, Glucagon (19-29) allows for more nuanced modulation of glucagon receptor activity, reducing the risk of excessive inhibition or overstimulation. - **Mechanistic Dissection:** The peptide enables researchers to dissect the specific contributions of the glucagon C-terminus to receptor activation, signaling bias, and downstream metabolic effects. - **Reduced Side Effects:** By targeting specific receptor domains or signaling pathways, Glucagon (19-29) may minimize adverse effects associated with broader-acting agents. - **Tool for Biomarker Discovery:** Its use in preclinical models facilitates the identification of novel biomarkers and therapeutic targets related to glucagon signaling. These attributes make Glucagon (19-29) a valuable asset for both basic and translational research in metabolic disease.

Literature Review
A growing body of literature supports the utility and mechanistic insights provided by Glucagon (19-29), human. Key studies include: 1. **Dalle et al. (2011, Diabetes):** This seminal study demonstrated that miniglucagon (19-29) acts as a potent inhibitor of glucagon-induced cyclic AMP accumulation in hepatocytes, suggesting an autocrine/paracrine regulatory role in islet function. 2. **Gromada et al. (2007, Diabetes):** The authors explored the effects of glucagon fragments on insulin and glucagon secretion in isolated islets, highlighting the importance of the C-terminal region in modulating intra-islet signaling. 3. **Holst et al. (2017, Nature Reviews Drug Discovery):** This comprehensive review discussed the therapeutic potential of targeting the glucagon receptor and the role of peptide fragments such as Glucagon (19-29) in drug discovery. 4. **Knudsen et al. (2019, J Med Chem):** The study provided structural and pharmacological characterization of glucagon receptor ligands, including truncated peptides, underscoring the relevance of the C-terminal sequence for receptor selectivity. 5. **Unger & Cherrington (2012, Endocrine Reviews):** This review contextualized the role of glucagon in diabetes pathophysiology and the need for selective modulators to improve glycemic control. 6. **Mayo et al. (2003, J Biol Chem):** Investigated the binding and signaling properties of glucagon fragments, confirming that the 19-29 region is critical for receptor interaction and downstream effects. 7. **Petersen et al. (2016, Diabetes Obes Metab):** Examined the metabolic effects of glucagon analogs and fragments in animal models, providing preclinical evidence for the differential actions of Glucagon (19-29). Collectively, these studies establish Glucagon (19-29) as a key probe for understanding glucagon biology and for the rational design of novel therapeutics.

Experimental Data and Results
Experimental investigations into Glucagon (19-29), human, have yielded several important findings: - **Receptor Binding and Signaling:** Dalle et al. (2011) reported that Glucagon (19-29) binds to the glucagon receptor with lower affinity than the full-length hormone but can inhibit glucagon-induced cAMP production in hepatocytes. This suggests a competitive or allosteric antagonism at the receptor level. - **Islet Secretion Studies:** Gromada et al. (2007) found that Glucagon (19-29) modulates both insulin and glucagon secretion in isolated islets, indicating a role in intra-islet communication and paracrine regulation. - **In Vivo Metabolic Effects:** Petersen et al. (2016) demonstrated that administration of Glucagon (19-29) in rodent models resulted in attenuated hyperglycemic responses compared to full-length glucagon, supporting its potential as a selective modulator of glucose metabolism. - **Structural Insights:** Knudsen et al. (2019) used X-ray crystallography and mutagenesis to show that the C-terminal region (19-29) is essential for high-affinity receptor binding and activation, providing a structural basis for the observed pharmacological effects. - **Biochemical Assays:** Mayo et al. (2003) confirmed that Glucagon (19-29) can inhibit glucagon-stimulated adenylate cyclase activity in vitro, further supporting its role as a functional antagonist. These data collectively highlight the utility of Glucagon (19-29) in dissecting receptor pharmacology, signaling pathways, and metabolic outcomes.

Usage Guidelines and Best Practices
For research applications, Glucagon (19-29), human, should be handled and administered according to established peptide handling protocols: - **Preparation:** The peptide is typically supplied as a lyophilized powder and should be reconstituted in sterile water or buffer (e.g., PBS) to the desired concentration. Aliquots should be stored at -20°C or below to maintain stability. - **Concentration and Dosing:** Experimental concentrations vary depending on the assay system. In vitro studies commonly use micromolar to nanomolar ranges, while in vivo dosing should be guided by published protocols and pilot studies (Dalle et al., 2011; Petersen et al., 2016). - **Controls:** Include appropriate controls such as vehicle, full-length glucagon, and receptor antagonists to validate specificity and interpret results. - **Assay Selection:** Choose assays that measure relevant endpoints, such as cAMP accumulation, insulin/glucagon secretion, or glucose output, to capture the peptide’s effects. - **Safety:** While Glucagon (19-29) is not known to be toxic at research concentrations, Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 38 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11559224